• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

Syn­dax's menin in­hibitor suc­ceeds in piv­otal tri­al, but in­vestors aren't im­pressed

5 months ago
R&D
Pharma

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

5 months ago
R&D
Pharma

In­ter­cept is de­nied full FDA ap­proval for Ocali­va, but claims it will keep drug on mar­ket

5 months ago
Pharma
FDA+

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

5 months ago
FDA+

Mer­ck KGaA plans Chi­na sub­mis­sion af­ter late-stage win for tu­mor drug

5 months ago
R&D
China

Apol­lo makes a deal worth up to $926M; Abeona re­sub­mits gene ther­a­py

5 months ago
News Briefing

Ex­clu­sive: GV-backed Med­ic­aid start­up Di­verge Health rais­es $52M

5 months ago
Financing
Health Tech

Up­dat­ed: As­traZeneca, Dai­ichi Sankyo re­place lung can­cer fil­ing for En­her­tu suc­ces­sor

5 months ago
R&D
Pharma

Bay­er not eye­ing new deals to ad­dress Xarel­to sales ero­sion

5 months ago
Pharma

As­traZeneca bud­gets an­oth­er $2B to boost man­u­fac­tur­ing and R&D in US

5 months ago
R&D
Manufacturing

Alen­tis nabs $181M to broad­en Claud­in's scope in AD­Cs

5 months ago
Financing
Startups

Roche teams with Flare Ther­a­peu­tics on tran­scrip­tion fac­tors

5 months ago
Startups
Deals

Maze's ALS spin­out Trace Neu­ro­science rais­es $101M for ALS and neu­ro work

5 months ago
Financing
Startups

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

5 months ago
R&D
AI

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

5 months ago
Deals
R&D

GSK snags Parkin­son's drug from Flag­ship start­up Vesal­ius

5 months ago
Startups
Deals

Neu­ro­gene's stock falls in post-mar­ket trad­ing af­ter ear­ly da­ta in Rett syn­drome

5 months ago
R&D
Cell/Gene Tx

23andMe to shut down its ther­a­peu­tics di­vi­sion

5 months ago
Pharma
Health Tech

Rapt cuts im­munol­o­gy pro­gram fol­low­ing clin­i­cal holds

5 months ago
Pharma
FDA+

FDA lifts hold on No­vavax vac­cines af­ter ad­verse event re­clas­si­fied as ALS

5 months ago
R&D
Pharma

Ther­mo Fish­er con­sol­i­dates vi­ral vec­tor work in Mass­a­chu­setts, cuts 160 work­ers 

5 months ago
People
Manufacturing

Yorvipath’s ap­proval show­cas­es bio­phar­ma’s in­ter­est in rare en­docrine dis­or­der

5 months ago
Startups
R&D

As­ser­tio de­nies ac­tivist in­vestor's claims of fraud in open let­ter

5 months ago
R&D

Crown jew­el from Ab­b­Vie's Cerev­el buy­out fails two Phase 2 schiz­o­phre­nia tests, Bris­tol My­er­s' stock soars

5 months ago
R&D
First page Previous page 66676869707172 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.